PURPOSE: Management of acanthamoeba keratitis remains challenging for ophthalmologists. We conducted a survey of members of The Cornea Society to elicit expert opinions on the diagnosis and treatment of acanthamoeba keratitis. METHODS: An online survey was sent to all subscribers of The Cornea Society via the kera-net listserv. Descriptive statistics were performed. RESULTS: Eighty-two participants completed the online survey. Of the 82 respondents, 76.8% included the combination of clinical examination and culture in their diagnostic strategy and 43.9% used confocal microscopy. Most respondents (97.6%) had used combination therapy with multiple agents to treat acanthamoeba keratitis at some point in the past, whereas a smaller proportion (47.6%) had ever used monotherapy. Respondents most commonly chose polyhexamethylene biguanide as the ideal choice for monotherapy (51.4%), and dual therapy with a biguanide and diamidine as the ideal choice for combination therapy (37.5%). The majority of respondents (62.2%) reported using topical corticosteroids at least some of the time for acanthamoeba keratitis. Keratoplasty was an option considered by most respondents (75.6%), although most (85.5%) would only perform surgery after medical treatment failure. CONCLUSIONS: There was a wide range of current practice patterns for the diagnosis and treatment of acanthamoeba keratitis. The lack of sufficiently powered comparative effectiveness studies and clinical trials makes evidence-based decision-making for this disease difficult.
PURPOSE: Management of acanthamoeba keratitis remains challenging for ophthalmologists. We conducted a survey of members of The Cornea Society to elicit expert opinions on the diagnosis and treatment of acanthamoeba keratitis. METHODS: An online survey was sent to all subscribers of The Cornea Society via the kera-net listserv. Descriptive statistics were performed. RESULTS: Eighty-two participants completed the online survey. Of the 82 respondents, 76.8% included the combination of clinical examination and culture in their diagnostic strategy and 43.9% used confocal microscopy. Most respondents (97.6%) had used combination therapy with multiple agents to treat acanthamoeba keratitis at some point in the past, whereas a smaller proportion (47.6%) had ever used monotherapy. Respondents most commonly chose polyhexamethylene biguanide as the ideal choice for monotherapy (51.4%), and dual therapy with a biguanide and diamidine as the ideal choice for combination therapy (37.5%). The majority of respondents (62.2%) reported using topical corticosteroids at least some of the time for acanthamoeba keratitis. Keratoplasty was an option considered by most respondents (75.6%), although most (85.5%) would only perform surgery after medical treatment failure. CONCLUSIONS: There was a wide range of current practice patterns for the diagnosis and treatment of acanthamoeba keratitis. The lack of sufficiently powered comparative effectiveness studies and clinical trials makes evidence-based decision-making for this disease difficult.
Authors: Truc H Nguyen; Robert W Weisenthal; George J Florakis; James J Reidy; Ronald N Gaster; Danita Tom Journal: Cornea Date: 2010-09 Impact factor: 2.651
Authors: Juan J Pérez-Santonja; Simon Kilvington; Reanne Hughes; Adnan Tufail; Melville Matheson; John K G Dart Journal: Ophthalmology Date: 2003-08 Impact factor: 12.079
Authors: L Daas; N Szentmáry; T Eppig; A Langenbucher; A Hasenfus; M Roth; M Saeger; B Nölle; B Lippmann; D Böhringer; T Reinhard; C Kelbsch; E Messmer; U Pleyer; S Roters; A Zhivov; K Engelmann; J Schrecker; L Zumhagen; H Thieme; R Darawsha; T Meyer-Ter-Vehn; B Dick; I Görsch; M Hermel; M Kohlhaas; B Seitz Journal: Ophthalmologe Date: 2015-09 Impact factor: 1.059
Authors: Ricardo Lamy; Elliot Chan; Samuel D Good; Vicky Cevallos; Travis C Porco; Jay M Stewart Journal: Clin Exp Ophthalmol Date: 2016-02-23 Impact factor: 4.207
Authors: Regis P Kowalski; Salwa Abdel Aziz; Eric G Romanowski; Robert M Q Shanks; Amy C Nau; Leela V Raju Journal: JAMA Ophthalmol Date: 2013-11 Impact factor: 7.389
Authors: Craig W See; Muthiah Srinivasan; Somu Saravanan; Catherine E Oldenburg; Elizabeth J Esterberg; Kathryn J Ray; Tanya S Glaser; Elmer Y Tu; Michael E Zegans; Stephen D McLeod; Nisha R Acharya; Thomas M Lietman Journal: Ophthalmic Epidemiol Date: 2012-12 Impact factor: 1.648